Top Tweets for #GLP1RAS
We had a paper accepted on significant improvement of #dysautonomia and #neuropathic pain with GLP-1 RAs. I'll share it when it's published.
#GLP1RAs might be our best, most affordable and most accessible therapeutic option for dysautonomia, #MECFS, #LongCOVID and #MCAS going forward, but we need randomized placebo-controlled trials.
✨New issue✨
Check out the latest in #Metabolism research from across all disciplines
Read about #PMOS, #PerineurialCells, #GLP1RAs, #MASLD, #PancreaticRemodeling, #Mitochondria and many more topics! 🧪🐭👥
https://t.co/6zA9chuA0A
👁️ Can rapid glucose lowering worsen #retinopathy? Prof David Matthews (EASD Past President) explains why sudden glycaemic shifts, not #GLP1RAs, pose risks for people with longstanding #diabetes. Who’s vulnerable & how to monitor?
📺🔗 Watch now: https://t.co/n86lyGIgEb
🚀From Bench to Paper | Neural Circuit Behind Oral Weight-Loss Drugs Revealed
A new study reveals a mechanistic breakthrough for oral small-molecule #GLP1 receptor agonists (#GLP1RAs). Using humanized mouse models, researchers show these compounds regulate both homeostatic feeding (energy balance) and hedonic feeding (reward-driven eating) 🍽️
Beyond classical metabolic pathways, GLP1RAs activate a distinct neuronal population in the central amygdala, which suppresses palatable food intake by reducing dopamine release in the nucleus accumbens.
• Activating this circuit reduces hedonic feeding 🍰
• Receptor deletion weakens reward-driven effects ⚖️
• Defines a brain pathway linking appetite and reward 🧠
These findings clarify how oral GLP1RAs modulate eating behavior, with implications for binge eating and potentially addiction-related disorders. Read more: https://t.co/t6UxHpOv6C
🔬MedChemExpress offers #Orforglipron to support this research. https://t.co/Z6J3CCaIpf
#Obesity #Neuroscience #MetabolicDisease #DrugDiscovery #BingeEating #MedChemExpress
@UNMC_IBD @UNMC_GIHEP @UNMCCOM @unmc @meaganreif @AmerGastroAssn @RomeFoundation @kehutchins77 @AASLDtweets @EASLnews @IBDimmunology @MedEdNurlan @DCharabaty 2nd last talk by me #GLP1RAs
🎯Consensus on Obesity and Cardiometabolic Comorbidities in IBD including role of GLP1 RAs is under process, with @P_DeepakIBDMD @amjohnsonMD @AndresYarur @phillyIBDdoc @SamiSamaanMD @EdBarnesMD
Martin Haluzík (@HaluzikMartin) Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
https://t.co/zvEYpnAN9W
#Diabetes #DM #GLP1RAS #Health #Hematology #Hemostasis #HemostasisNews #HemostasisToday #LEA #MALE #Medicine #Obesity #PAD #SOUL #STRIDE #T2DM #Thrombosis
💉#GLP1RAs & #SGLT2i: gut → heart → kidney
GLP-1RA / SGLT2i → 🦠 Gut microbiota ↑
↑ Akkermansia & Faecalibacterium → ↓ LPS
→ ↑ SCFAs & gut barrier
→ ↓ inflammation & atherosclerosis
→ ↓ proteinuria + ↑ insulin sensitivity
🔗https://t.co/vCdDVKazb9
#Nephrology
Beyond weight loss & glycemic control—can #GLP1RAs reduce #Arrhythmias? 🤔
📊 In our recently published large real-world study of >650,000 matched patients with obesity, GLP-1 RA use was associated with 📉 lower risk of cardiac arrest, AF/flutter, VT/VF & heart block 🫀💊
Could GLP-1RAs be the solution needed to address weight gain and enhance adherence in psychiatric treatments? Discover their potential to improve cardiometabolic health for psychotropic patients. #Psychiatry #GLP1RAs #MentalHealth
📢Among 296K+ adults with #T2D across 6 #UShealthsystems—including Geisinger—#GLP1RAs came out on top for MACE reduction. Sarah Dombrowski and @RxEricWright led Geisinger’s efforts on this real-world study! 💊 #GeisingerCPIO https://t.co/iCz4VqO10R
In adults with type 2 #diabetes, #GLP1 RAs were most protective against major cardiovascular events, followed by SGLT2is, sulfonylureas, and DPP4is, with greatest benefit in those with #heartdisease, heart failure, older age, or kidney impairment. https://t.co/fhC90TXDBN
Excited to share our study on #GLP1RAs in primary prevention! After 44 weeks, a 13.45% relative reduction in 10-year ASCVD risk in high-risk people with T2D and no prior CVD. @cardiologiaCHUS @angelsalbar @FAPsGal @MoisesManero @acorderofort @JoseJuanatey https://t.co/jQHrkw7MEB
It's intriguing to see #GLP1RAs being explored for idiopathic intracranial #hypertension. Could this be a shift towards metabolic regulation as a treatment direction for such conditions? What might be the underlying mechanisms at work here? For those who are interested in diving deeper into biomedical questions and literature reviews, check out https://t.co/4Y9Imt8uIJ - it's your one-stop platform for comprehensive information and review generation. #Medicine
📊Can #GLP1RAs provide benefits for adults with #T1D and #obesity already using #AID systems?
Prof. Janet Snell-Bergeon shares results from the ADJUST-T1D trial regarding #WeightLoss, #InsulinRequirement, #GlycaemicControl.
📺Watch the latest ep. now: https://t.co/zAD8P8oFvN
Grateful to be featured in the Advances in Science Session at #ESC2025 🇪🇸and present our findings on #CA and #GLP1RAs in #HFpEF. An unforgettable experience sharing the stage with giants in the field!
@escardio @UTSWIMchief @UTSWInternalMed @utswheart
https://t.co/2FUj21kRzi
📢NEW: August issue now online featuring #RSV, #GLP1RAs, #sepsis, #IBD, #cardiomyopathy, #BreastCancer, #Covid, #HIV, #stroke, and much more with our editorial on happiness and health
all available #free, #OpenAccess❗️
Read more here: https://t.co/mSjmBU6GQY
Attribution: Getty
Relative to other second-line therapies, #GLP1RAs were not associated with an increased risk for #ThyroidCancer among patients with #T2D.
@FannyBu214 @MichaelEMatheny @wallis_lau @KennethKCMan @JINJINZHOU @TDuarte_Salles @hmkyale @rohan_khera
https://t.co/ete2ui8NwH
#GLP1RAs were associated with improved #QualityOfLife metrics and #EmotionalEating behaviors among individuals with #overweight and #obesity.
@KingsIoPPN @GSTTnhs @ImperialMed @UniofOxford @OxfordHealthNHS @rdegiorgi @tobypill
https://t.co/K8w9KJZ6cK
📣 Read our new meta-analysis on @JAMAPsych https://t.co/TD9OKfGkDD investigating #GLP1RAs and mental health outcomes in people with T2DM and obesity - an important study led by Aureliane Pierret & @tobypill
Pleased to share our study demonstrating use of #GLP1RAs in women with #PCOS results in similar weight loss compared to controls without PCOS. @aepcossociety @PennOBGYN @pcoschallenge @veritypcos @acog @FertStert https://t.co/PHcyDi3JaH
#GLP1RAs were associated with similar #WeightLoss outcomes among patients with vs without #PCOS in a real-world setting.
@PennMedicine @AnujaDokras
https://t.co/f5K9XYqJhr
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers